Manuel Calvin, MD
Rheumatology · Tulsa, OKNPI 1396744678
Payments from drug & device makers
Across 1,131 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Amgen$4K
- UCB, Inc.$1K
- Johnson & Johnson$1K
- Novartis$1K
- Pfizer$1K
- plus $6K from 31 others
What the payments were for
- Food & beverage$18,91898%
- Education$4632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 348 | $5,086 |
| Amgen(2 entities) | 213 | $3,784 |
| UCB, Inc. | 81 | $1,410 |
| Johnson & Johnson | 58 | $1,232 |
| Novartis | 69 | $1,094 |
| Pfizer | 69 | $1,068 |
| GSK | 54 | $878 |
| Lilly USA, LLC | 38 | $820 |
| AstraZeneca(2 entities) | 37 | $661 |
| Genentech USA, Inc. | 28 | $516 |
| Mallinckrodt Hospital Products Inc. | 25 | $487 |
| E.r. Squibb & Sons, L.L.C. | 24 | $421 |
| Aurinia Pharma U.S., Inc. | 16 | $263 |
| Boehringer Ingelheim | 11 | $230 |
| Actelion Pharmaceuticals US, Inc. | 9 | $228 |
| Sanofi | 4 | $216 |
| ANI Pharmaceuticals, Inc. | 8 | $196 |
| Sobi, Inc | 7 | $190 |
| Amarin Pharma, Inc. | 4 | $74 |
| La Jolla Pharmaceutical Company | 1 | $69 |
| Sandoz | 2 | $51 |
| Collegium Pharmaceutical, Inc. | 3 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Organon | 2 | $44 |
| Antares Pharma, Inc. | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Almatica Pharma LLC | 1 | $11 |
How this compares
$19,381 in reported general payments places this provider in the 70th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 87 | $656,834 |
| Humira(Cf) PenAdalimumab | 79 | $610,618 |
| RinvoqUpadacitinib | 58 | $382,897 |
| Xeljanz XrTofacitinib Citrate | 54 | $339,974 |
| SimponiGolimumab | 30 | $252,760 |
| Orencia ClickjectAbatacept | 46 | $251,186 |
| OrenciaAbatacept | 35 | $192,564 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 20 | $146,530 |
| BenlystaBelimumab | 19 | $141,383 |
| Enbrel MiniEtanercept | 16 | $137,679 |
| Cosentyx Sensoready PenSecukinumab | 14 | $123,090 |
| EnbrelEtanercept | 14 | $120,306 |
| OtezlaApremilast | 21 | $102,777 |
| Taltz AutoinjectorIxekizumab | 15 | $101,756 |
| OlumiantBaricitinib | 20 | $84,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $5,086 | $391,07873 claims |
| Johnson & JohnsonSimponi | $1,232 | $252,76030 claims |
| AmgenEnbrel, Otezla | $3,784 | $223,08335 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $421 | $192,56435 claims |
| GSKBenlysta | $878 | $141,38319 claims |
| Lilly USA, LLCOlumiant | $820 | $84,82320 claims |
| PfizerXeljanz | $1,068 | $68,05512 claims |
| Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca, Xtampza Er | $48 | $47,86041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Tulsa
- Basmah JalilTulsa$5.2M
- James McKayTulsa$945K
- Debbie FoleyTulsa$488K
- William SurbeckTulsa$82K
- Ellen ZanetakisTulsa$80K
- Alan MartinTulsa$22K
- Mary Hinojos MamutTulsa$21K
- Michael MalloyTulsa$13K
- Priyatha GarlapatiTulsa$8K
- Lindsay CunninghamTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.